CO6220962A2 - Usos terapeuticos novedosos de 1-[2(2,4-dimetilfenilsulfanil)fenil]-piperazina - Google Patents

Usos terapeuticos novedosos de 1-[2(2,4-dimetilfenilsulfanil)fenil]-piperazina

Info

Publication number
CO6220962A2
CO6220962A2 CO09100115A CO09100115A CO6220962A2 CO 6220962 A2 CO6220962 A2 CO 6220962A2 CO 09100115 A CO09100115 A CO 09100115A CO 09100115 A CO09100115 A CO 09100115A CO 6220962 A2 CO6220962 A2 CO 6220962A2
Authority
CO
Colombia
Prior art keywords
acid addition
compound
piperazine
phenyl
addition salt
Prior art date
Application number
CO09100115A
Other languages
English (en)
Inventor
Nicholas Moore
Tine Bryan Stensbol
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39564604&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6220962(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/DK2007/050075 external-priority patent/WO2007144005A1/en
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of CO6220962A2 publication Critical patent/CO6220962A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

1.- Un método para el tratamiento del dolor o de los 4 síntomas residuales en la depresión, comprendiendo el método la administración de una cantidad eficaz para uso terapéutico de 1-[2-(2,4-dimetilfenilsulfanil)fenil]piperazina y sus sales de adición de ácido aceptables para uso farmacéutico (compuesto I) a un paciente que lo necesita.2.- El método de acuerdo con la reivindicación 1, donde el compuesto l es la sal de adición de ácido HBr. 3.- El método de acuerdo con la reivindicación 2, donde dicha sal de adición de ácido HBr es cristalina con reflexiones de XRPD en 6,89, 9,73, 13,78 y 14,64 (°2?). 4.- El método de acuerdo con la reivindicación 3, donde dicha sal de adición de ácido HBr tiene una XRPD según lo ilustrado en la Figura 3. 5.- El método de acuerdo con cualquiera de las reivindicaciones 1-4, donde el compuesto I se administra en dosis diarias de aproximadamente 1-20 mg. 6.- El uso de 1-[2-(2,4-dimetilfenilsulfanil)fenil]piperazina y sus sales de adición de ácido aceptables para uso farmacéutico (compuesto I) en la manufactura de un medicamento para el tratamiento del dolor o de los síntomas residuales en la depresión. 7.- El uso de acuerdo con la reivindicación 6, donde el compuesto les la sal de adición de ácido HBr. 8.- El uso de acuerdo con la reivindicación 7, donde dicha sal de adición de ácido HBr es cristalina con reflexiones de XRPD en 6,89, 9,73, 13,78 y 14,64 (°2?). 9.- El uso de acuerdo con la reivindicación 8, donde dicha sal de adición de ácido HBr tiene una XRPD según lo ilustrado en la Figura 3. 10.- El uso de acuerdo con cualquiera de las reivindicaciones 6-9, donde dicho fármaco está destinado a la administración en dosis diarias de aproximadamente 1-20 mg. 11.- 1 -[2-(2,4-dimetilfenilsulfanil)fenil]piperazina y sus sales de adición de ácido aceptables para uso farmacéutico (compuesto I) para utilizar en el tratamiento del dolor o de los síntomas residuales en la depresión.
CO09100115A 2007-03-20 2009-09-16 Usos terapeuticos novedosos de 1-[2(2,4-dimetilfenilsulfanil)fenil]-piperazina CO6220962A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200700427 2007-03-20
PCT/DK2007/050075 WO2007144005A1 (en) 2006-06-16 2007-06-15 1- [2- (2, 4-dimethylphenylsulfanyl) -phenyl] piperazine as a compound with combined serotonin reuptake, 5-ht3 and 5-ht1a activity for the treatment of cognitive impairment

Publications (1)

Publication Number Publication Date
CO6220962A2 true CO6220962A2 (es) 2010-11-19

Family

ID=39564604

Family Applications (1)

Application Number Title Priority Date Filing Date
CO09100115A CO6220962A2 (es) 2007-03-20 2009-09-16 Usos terapeuticos novedosos de 1-[2(2,4-dimetilfenilsulfanil)fenil]-piperazina

Country Status (29)

Country Link
US (1) US8664225B2 (es)
EP (1) EP2142193B1 (es)
JP (1) JP5371790B2 (es)
KR (1) KR101459168B1 (es)
CN (2) CN101636161A (es)
AR (1) AR065797A1 (es)
AT (1) ATE495745T1 (es)
AU (1) AU2008228638B2 (es)
BR (1) BRPI0808941A2 (es)
CA (1) CA2684571C (es)
CL (1) CL2008000795A1 (es)
CO (1) CO6220962A2 (es)
CY (1) CY1111183T1 (es)
DE (1) DE602008004643D1 (es)
DK (1) DK2142193T3 (es)
EA (1) EA017058B1 (es)
ES (1) ES2355434T3 (es)
HR (1) HRP20110058T1 (es)
IL (2) IL200956A (es)
MX (1) MX2009009672A (es)
MY (1) MY150448A (es)
NZ (1) NZ579721A (es)
PL (1) PL2142193T3 (es)
PT (1) PT2142193E (es)
RS (1) RS51560B (es)
SI (1) SI2142193T1 (es)
TW (1) TW200848411A (es)
UA (1) UA97392C2 (es)
WO (1) WO2008113359A2 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2044043T2 (sl) * 2006-06-16 2021-04-30 H. Lundbeck A/S 1-2(-2,4-dimetilfenilsulfanil)-fenil)piperazin hidrobromid kot spojina s kombinirano aktivnostjo ponovnega privzema serotonina, 5-ht3 in 5-ht1a za zdravljenje kognitivne motnje
AU2014200364B2 (en) * 2007-11-13 2015-09-17 H. Lundbeck A/S Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1A activity
TW200932233A (en) 2007-11-13 2009-08-01 Lundbeck & Co As H Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1a activity
TW201033181A (en) * 2009-02-17 2010-09-16 Lundbeck & Co As H Purification of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine
NZ596431A (en) * 2009-04-24 2012-12-21 Lundbeck & Co As H Liquid formulations of salts of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine
SI2470166T1 (sl) 2009-08-24 2014-03-31 H.Lundbeck A/S Novi sestavki 1-(2-(2,4-dimetil-fenislulfanil)-fenil)piperazina
JP5787882B2 (ja) * 2010-04-30 2015-09-30 武田薬品工業株式会社 腸溶性錠剤
TW201212918A (en) 2010-08-23 2012-04-01 Lundbeck & Co As H Therapeutic uses of 1-[2-(2,4-dimethyl-phenylsulfanyl)phenyl]piperazine
US9499504B2 (en) 2012-09-19 2016-11-22 Sandoz Ag Crystalline form of vortioxetine hydrobromide
CN104736526B (zh) 2013-09-12 2016-04-20 杭州普晒医药科技有限公司 沃替西汀盐及其晶体、它们的制备方法、药物组合物和用途
EP2878596A1 (en) * 2013-11-29 2015-06-03 LEK Pharmaceuticals d.d. Synthesis of vortioxetine via (2-(piperazine-1-yl)phenyl)lithium intermediates
RU2679661C1 (ru) 2013-12-20 2019-02-12 Х. Лундбекк А/С Применение антагониста опиоидных рецепторов с k-активностью и вортиоксетина для лечения депрессивного расстройства с меланхолическими признаками
US9822086B2 (en) 2014-01-31 2017-11-21 Egis Gyogyszergyar Zrt. Process for the preparation of vortioxetine salts
CN104059030B (zh) 2014-05-30 2016-05-04 镇江圣安医药有限公司 [(苯硫烷基)-苯基]哌嗪的衍生物及其药物组合物和用途
CN105198837B (zh) * 2014-06-09 2018-05-04 上海医药工业研究院 一种沃替西汀氢溴酸盐晶体及其制备方法
CN104610195B (zh) * 2015-01-30 2017-06-27 上虞京新药业有限公司 沃替西汀的天冬氨酸盐或其水合物及其制备方法和用途
CN106279066A (zh) * 2015-05-22 2017-01-04 天津药物研究院有限公司 一种氢溴酸沃替西汀晶体的纯化方法
CN106556663B (zh) * 2015-09-30 2018-05-29 成都弘达药业有限公司 一种1-[2-(2,4-二甲基苯基硫烷基)苯基]哌嗪或其盐的检测方法
JP2019525900A (ja) 2016-06-16 2019-09-12 サンシャイン・レイク・ファーマ・カンパニー・リミテッドＳｕｎｓｈｉｎｅ Ｌａｋｅ Ｐｈａｒｍａ Ｃｏ．，Ｌｔｄ． ジアリールチオエーテルピペラジン化合物、その調製方法及び使用
US9820984B1 (en) 2016-07-01 2017-11-21 H. Lundbeck A/S Dosing regimens for fast onset of antidepressant effect
JP7121751B2 (ja) 2017-04-25 2022-08-18 ハー・ルンドベック・アクチエゼルスカベット ボルチオキセチンＨＢｒ α型を製造するための方法
KR102026337B1 (ko) 2017-07-07 2019-09-27 영진약품 주식회사 1-[2-(2,4-디메틸페닐설파닐)페닐]피페라진의 신규염 및 이의 제조방법
WO2023036820A1 (en) 2021-09-10 2023-03-16 H. Lundbeck A/S Therapeutic uses of 1-[2-(2,4-dimethyl-phenylsulfanyl)phenyl]piperazine

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA76130C2 (en) * 2000-11-20 2006-07-17 Merck Patent Gmbh Use of compounds combining properties of selective inhibitors of serotonin re-uptake and agonists of 5-ht1a receptor for treatment of irritable bowel syndrome
UA81749C2 (uk) * 2001-10-04 2008-02-11 Х. Луннбек А/С Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну
ES2280595T3 (es) * 2001-12-20 2007-09-16 H. Lundbeck A/S Derivados de ariloxifenilo y arilsulfanilfenilo.
SI2044043T2 (sl) * 2006-06-16 2021-04-30 H. Lundbeck A/S 1-2(-2,4-dimetilfenilsulfanil)-fenil)piperazin hidrobromid kot spojina s kombinirano aktivnostjo ponovnega privzema serotonina, 5-ht3 in 5-ht1a za zdravljenje kognitivne motnje

Also Published As

Publication number Publication date
BRPI0808941A2 (pt) 2014-08-19
EA017058B1 (ru) 2012-09-28
EP2142193B1 (en) 2011-01-19
ATE495745T1 (de) 2011-02-15
CL2008000795A1 (es) 2008-09-26
DE602008004643D1 (de) 2011-03-03
JP2010521501A (ja) 2010-06-24
UA97392C2 (ru) 2012-02-10
AR065797A1 (es) 2009-07-01
CN101636161A (zh) 2010-01-27
CY1111183T1 (el) 2015-06-11
WO2008113359A3 (en) 2008-11-13
WO2008113359A2 (en) 2008-09-25
US8664225B2 (en) 2014-03-04
ES2355434T3 (es) 2011-03-25
KR20090125251A (ko) 2009-12-04
RS51560B (en) 2011-06-30
PL2142193T3 (pl) 2011-04-29
KR101459168B1 (ko) 2014-11-07
CA2684571C (en) 2012-08-14
AU2008228638A1 (en) 2008-09-25
CN103948597A (zh) 2014-07-30
EA200970870A1 (ru) 2010-04-30
EP2142193A2 (en) 2010-01-13
MY150448A (en) 2014-01-30
IL200956A (en) 2015-05-31
CA2684571A1 (en) 2008-09-25
NZ579721A (en) 2011-07-29
TW200848411A (en) 2008-12-16
IL238068A0 (en) 2015-05-31
AU2008228638B2 (en) 2012-09-20
PT2142193E (pt) 2011-02-02
JP5371790B2 (ja) 2013-12-18
MX2009009672A (es) 2009-12-15
SI2142193T1 (sl) 2011-03-31
HRP20110058T1 (hr) 2011-03-31
DK2142193T3 (da) 2011-03-28
US20110009422A1 (en) 2011-01-13
IL200956A0 (en) 2010-05-17

Similar Documents

Publication Publication Date Title
CO6220962A2 (es) Usos terapeuticos novedosos de 1-[2(2,4-dimetilfenilsulfanil)fenil]-piperazina
ECSP088973A (es) Derivados de imidazol pirimidina para el tratamiento de enfermedades relacionadas con la glicógeno sintasa quinasa (gsk3)
ECSP088974A (es) Derivados de imidazol pirimidina para el tratamiento de enfermedades relacionadas con la glicógeno sintasa quinasa (gsk3)
AR039164A1 (es) Sales de venlafaxina de baja solubilidad en agua
CO6220957A2 (es) 4-2-(4-metilfenilsulfanil-fenil piperidina con inhibicion combinada de recaptacion de serotonina y norepinefrina para el tratamiento del trastorno de deficit de atencion e hiperactividad melancolia depresion resistente al tratamiento o sintomas resid
PE20040134A1 (es) Forma de dosificacion de una vez al dia de pramipexol
CL2011001927A1 (es) Uso de una composicion farmaceutica de liberacion sostenida, que comprende como ingrediente activo a 4-aminopiridina, que sirve para preparar un medicamento util para el tratamiento de la esclerosis multiple, en dos dosis de 10 miligramos diarias, que permite recuperar la marcha de un paciente afectado.
PE20170302A1 (es) Uso de pridopidina en dosis altas para el tratamiento de enfermedad de huntington
AR070047A1 (es) Tratamientos terapeuticos contra el cancer. composicion que comprende un inhibidor de hedgehog.
AR059723A2 (es) Composicion de altas dosis de ibandronato
RU2013121788A (ru) Ингибиторы репликации вич
SV2009002857A (es) Formas de presentacion farmaceutica solidas de administracion oral con liberacion rapida de principio activo
EA200700214A1 (ru) Мемантин в качестве дополнительной терапии к атипичным антипсихотическим средствам у больных шизофренией
UY31609A1 (es) "(-) ácido 2-[1-(7-metil-2-(morfolin-4-il) 4-oxo-4h-pirido[1,2-a]pirimidin-9-il)etilamino]benzoico enantioméricamente puro, su uso en terapia médica, y una composición farmacéutica que lo comprende-026."
AR065731A1 (es) Composiciones farmaceuticas que contienen 2-[6-(3-amino-pipenidin-1-il)-3-metil-2,4-dioxo-3,4-dihidro-2h-primidin-1-il metil]-4-fluoro-benzonitrilo. uso. metodo de tratamiento, administracion semanal de inhibidores de la dipeptidilpeptidasa.
AR076400A1 (es) Formulaciones liquidas de sales de 1-(2-(2,4-dimetilfenilsulfanil)fenil)piperazina, uso, la sal y recipiente
AR078224A1 (es) Composicon para el tratamiento del cancer de prostata
AR020803A1 (es) Una composicion que comprende fexofenadina o una sal farmaceuticamente aceptable de la misma y el uso de la misma para la manufactura de unmedicamento
ES2542842T3 (es) Composición que comprende taurolidina y/o taurultam para el tratamiento del cáncer
AR061166A1 (es) Composiciones farmaceuticas para la liberacion sostenida de fenilferina
CL2021003034A1 (es) Métodos de tratamiento del síndrome de sjögren utilizando un inhibidor de la tirosina quinasa de bruton
AR073265A1 (es) Uso de dronedarona para la preparacion de un medicamento para la prevencion de ictus o ataque isquemico transitorio
AR043259A1 (es) Metodo para el tratamiento de insuficiencia cardiaca severa y medicamento para ello
CL2021003032A1 (es) Métodos de tratamiento de la urticaria crónica espontánea utilizando un inhibidor de la tirosina quinasa de bruton
AR029666A1 (es) Uso del (+) -alfa-(2,3-dimetoxifenil)-1-[2-(4-fluorofenil)etil]-4-piperidinmetanol o su prodroga para la manufactura de un medicamento en el tratamiento de los sintomas de la demencia y de la psicosis inducida por dopamina

Legal Events

Date Code Title Description
FC Application refused